Sage Therapeutics Inc. Stock
Sage Therapeutics Inc. Stock
There is an upward development for Sage Therapeutics Inc. compared to yesterday, with an increase of €0.18 (1.580%).
Currently there is a rather positive sentiment for Sage Therapeutics Inc. with 5 Buy predictions and 3 Sell predictions.
With a target price of 26 € there is potential for a 132.14% increase which would mean more than doubling the current price of 11.2 € for Sage Therapeutics Inc..
So far the community has only identified positive things for Sage Therapeutics Inc. stock. The most positive votes were given for criterium "Valuation (undervalued/overvalued)".
Pros and Cons of Sage Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sage Therapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Sage Therapeutics Inc. | 1.580% | 4.089% | -10.543% | -77.328% | -44.000% | -81.693% | - |
Ironwood Pharmaceuticals | 0.840% | -0.826% | -20.000% | -37.500% | -41.176% | -40.594% | - |
Novocure Ltd | 3.720% | 13.230% | 93.040% | -70.693% | 53.485% | -85.261% | - |
Iovance Biotherapeutics Inc. | 0.930% | -2.727% | -10.108% | 29.434% | 22.439% | -35.493% | - |
Comments
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $28.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $29.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for SAGE provided by MarketBeat
News
5 Biotech stocks tapping into unmet mental health treatment needs
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are